25 results
8-K
EX-99.2
RPTX
Repare Therapeutics Inc
7 May 24
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
4:10pm
improved selectivity vs AurB Clean in PanLabs safety pharmacology screen 1 CFI-400945 and EXEL-7871. Source: internal data and Exelixis corporate … regressions Highly potent, selective and orally bioavailable Polθ ATPase inhibitor; clean PanLabs safety pharmacology screen RP-3467 demonstrated complete
8-K
EX-1.1
lqboh
1 Nov 21
Repare Therapeutics Announces Proposed Public Offering of Common Shares
4:52pm
10-K
ktil5w26wbn2vrgmf
4 Mar 21
Annual report
5:25pm
10-Q
1nkbwapnq2 nlb5
13 Aug 20
Quarterly report
4:12pm
424B4
fve6hr 68ps0zig
19 Jun 20
Prospectus supplement with pricing info
4:38pm
S-1/A
2vf5u9
15 Jun 20
IPO registration (amended)
6:18am
S-1/A
EX-10.14
qe264pgxj qqs5
15 Jun 20
IPO registration (amended)
6:18am
S-1
8kd ukxqca
29 May 20
IPO registration
5:26pm